Vertex's Rocky September Causes Vetr To Urge Sell

The Vetr crowd on Wednesday downgraded its rating of Vertex Pharmaceuticals Incorporated VRTX from 5 stars (Strong Buy), issued 15 days ago, to 1 star (Strong Sell). Crowd sentiment at the time of the downgrade was generally cautious, with 68 percent of Vetr user ratings bearish.

Vetr's downgrade comes as share price in Vertex hit a September low, closing Wednesday's session at $152.72. The stock has experienced a steady downward trend throughout the month after peaking at $163.15, close to its all-time high of $166.11 set last July.

This negative price trend was exacerbated when, on Sept. 11, the company announced it would be shutting down a study it was conducting toward a long-acting Kalydeco to treat cystic fibrosis. However, the pharmaceutical company insists that development of the treatment is still progressing.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target on Vertex is down at $140.20, which is still well above the average analyst price target of $108.10. Less than 2 percent of Vetr users are holding VRTX in their watch-lists.